SM DERMA

PRODUCTS RESEARCH &DEVELOPMENT REPORT

Article No.003

Exosomes — The Future Raw Material for Innovative Skincare Solutions

Issue date: 2025-Sept-22

SM DERMA R&D Department

ARTICLE INFO

Keywords:
Exosome
Dermatological
Stem cell
Cosmeceutical

ABSTRACT

Exosomes, nanoscale extracellular vesicles (EVs) secreted by most cell types, carry proteins, lipids, and nucleic acids that mediate intercellular communication. Their ability to promote cell proliferation, modulate inflammation, and remodel the extracellular matrix positions them as a compelling cell-free alternativefor regenerative skincare. SM DERMA's exosomes—derived from selected human and plant stem-cell conditioned media—are reported at 155 ± 61.5 nmwith a concentration of 7×10^9 particles/mLand undergo sterilization and strict batch quality control. This review summarizes current scientific rationales for exosome use in dermatological and cosmetic formulations, compares SM DERMA's reported product specifications with literature benchmarks, examines preclinical and early clinical evidence, and highlights regulatory and ethical considerations essential for safe commercial translation.

1. Introduction

Exosomes are membrane-bound vesicles (30–200 nm)that transfer bioactive cargo—proteins, microRNAs, and lipids—to recipient cells, orchestrating paracrine signaling central to tissue homeostasis and repair. In cutaneous biology, exosomes derived from stem cells and other regenerative cell types have demonstrated the ability to:

- reduce inflammatory cytokines,

- enhance keratinocyte and fibroblast proliferation and migration

- stimulate collagen and elastin synthesis, and

- accelerate wound closure and angiogenesis.

These properties align closely with the goals of anti-aging and repair-oriented skincare. Compared with live-cell therapies, exosomes offer a cell-free, stable, and ethically manageableapproach that retains the core therapeutic signaling of their parent cells.

2. Source Material — Human vs. Plant Stem-Cell Conditioned Media

Conditioned media (CM) obtained from stem-cell cultures contain soluble growth factors and EVs, including exosomes. Human stem-cell conditioned media are rich in cytokines and genetic regulators of collagen homeostasis and wound healing. However, concerns regarding immunogenicity and regulatory hurdles have led to increased interest in plant stem-cell secretomes and EV-like particles.

SM DERMA's dual sourcing—from both human and plant stem-cell CM—mirrors an emerging trend to blend human regenerative signalingwith plant-derived antioxidant and anti-UV properties, aiming to achieve balanced safety and efficacy. Such an approach requires robust isolation, purification, and characterization processes to ensure consistency, sterility, and functional integrity.

3. Characterization and Quality Control — Comparing Specifications

Reported SM DERMA specifications:

✔ Modal particle size:155.0 ± 61.5 nm

✔ Concentration:7×10^9 particles/mL

✔ Processing:Sterilization + batch-specific QC

Comparison with Literature

Scientific reports generally describe small EVs of 30–150 nm. Variations arise due to analytical techniques: dynamic light scattering (DLS) often yields larger mean diameters than nanoparticle tracking analysis (NTA), while electron microscopy (TEM or cryo-EM) confirms morphology. A modal size around 155 nm ± 61.5 nm remains within an acceptable experimental range if polydispersity is accounted for.

Typical exosome concentrations in purified suspensions range from 10^8 to 10^{10} particles/mL —consistent with SM DERMA's values. Comprehensive quality assurance should include orthogonal characterization(NTA + TEM/cry-EM), immunomarker validation(CD9, CD63, CD81), and endotoxin/sterility testingto ensure product safety and reproducibility.

4. Mechanisms of Action Relevant to Skincare

Preclinical research attributes the regenerative and aesthetic benefits of exosomes to several convergent mechanisms:

✔ Immunomodulation:down-regulation of TNF-α and IL-6, promoting a regenerative microenvironment.

✔ Proliferation & Migration:stimulation of keratinocytes and fibroblasts, accelerating epithelial repair.

✔ Matrix Remodeling:activation of collagen I/III and elastin synthesis, improving tensile strength and dermal density.

✔ Angiogenesis:promotion of vascular endothelial growth factor (VEGF) pathways to restore oxygenation and nutrient flow.

Together, these mechanisms provide a coherent biological rationale for incorporating exosomes into anti-aging and post-procedure skincare formulations.

5. Clinical Evidence and Translational Status

Clinical evaluation of exosome-based aesthetic treatments remains in its infancy. Early pilot studies report improvements in wrinkle depth, skin texture, and pigmentationwhen exosomes are delivered via microneedling or fractional laser systems. However, randomized, placebo-controlled trialswith standardized outcome measures are still limited.

Current evidence supports biological plausibility and preliminary efficacy, but further controlled investigations are required to define optimal dosing, delivery frequency, and safety parameters before full regulatory acceptance in cosmetics or dermatology.

6. Formulation, Stability, and Delivery Considerations

Maintaining exosome integrity during formulation and topical application is a major technical challenge. Strategies to enhance stability and dermal delivery include:

Physical delivery adjuncts:microneedling, iontophoresis, or fractional lasers to bypass the stratum corneum.

Encapsulation and lyophilization:using stabilizers (trehalose, albumin) to protect membrane structure during storage.

Cold-chain logistics:maintaining 2–8 °C storage with validated sterilization to preserve bioactivity.

SM DERMA's emphasis on sterilization and batch-specific QCaligns with these best practices. Future validation should report shelf-life data, potency retention, and compatibilitywith common cosmetic excipients.

7. Safety, Regulatory, and Ethical Issues

Regulatory agencies worldwide adopt cautious stances on human-derived biologicsin consumer products. Risks include contamination, adventitious viral particles, and mislabeling of cell-derived materials. Cases of unregulated exosome use in aesthetic clinics underscore the need for traceability, donor documentation, and GMP compliance.

Manufacturers must therefore ensure:

✔Verified donor/source documentation (for human CM).

✔Full sterilization and endotoxin testing records.

✔Clear product classification (cosmetic vs medicinal) under local regulations.

Ethical use demands transparency in sourcing and truthful marketing to avoid misuse or consumer deception.

8. Positioning and Recommended Validation Steps

SM DERMA provides measurable particle metrics and sterilization assurances. To elevate scientific credibility and regulatory confidence, the following steps are recommended:

8.1 Analytical publication:report NTA/TEM data, exosome marker expression, endotoxin and sterility test results.

8.2 Stability and formulation studies:document potency retention across shelf-life and storage conditions.

8.3 Functional bioassays:fibroblast proliferation, collagen gene expression, and anti-inflammatory activity to confirm lot consistency.

8.4 Controlled clinical trials:investigator-blinded studies with quantitative endpoints (histology, imaging, patient-reported outcomes).

8.5 Regulatory transparency:provide GMP certification, donor/source traceability, and cosmetic compliance documentation.

9. Conclusion

Exosomes represent one of the most promising frontiers in biotechnology-driven skincare. Their multifaceted regenerative mechanisms—ranging from immune modulation to ECM remodeling—make them an ideal raw material for advanced cosmetic formulations. SM DERMA's preliminary physicochemical characterization and emphasis on sterilization mark strong foundational steps.

To fully realize the potential of exosome-based skincare, comprehensive validation through analytical, functional, and clinical studiesis essential. When developed under rigorous scientific and regulatory frameworks, exosomes

may redefine the standards of efficacy and safety in regenerative dermatology.

Key References and Suggested Reading

1. Tan F. et al.Clinical Applications of Stem-Cell-Derived Exosomes.Nature, 2024 — Highlights translational potential of stem-cell exosomes.

2. Alquraisy A. et al.A Comprehensive Review of Stem-Cell Conditioned Media.Frontiers in Cell & Developmental Biology, 2024 — Examines CM effects on skin aging and repair.

3. Arab T. et al.Characterization of Extracellular Vesicles and Synthetic Particles: Orthogonal Technologies.Journal of Extracellular Vesicles, 2023 — Compares sizing and quantification methods.

4. Zhao H. et al.Bioengineered MSC-Derived Exosomes in Skin Wound Healing.Frontiers in Bioengineering and Biotechnology, 2024 — Describes mechanisms and biomaterial integration.

5. The Guardian.Investigative Report on Regulatory Oversight of Human-Derived Exosome Treatments in Aesthetic Clinics, 2023 — Highlights ethical and safety concerns.